Outset Medical, Inc. (NASDAQ:OM – Get Rating) Director James F. Hinrichs bought 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, November 22nd. The shares were purchased at an average cost of $17.84 per share, with a total value of $133,800.00. Following the acquisition, the director now directly owns 47,668 shares of the company’s stock, valued at $850,397.12. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.
Outset Medical Stock Up 11.1 %
Shares of NASDAQ:OM opened at $19.94 on Friday. Outset Medical, Inc. has a 12-month low of $11.41 and a 12-month high of $51.69. The business has a 50 day moving average of $15.88 and a two-hundred day moving average of $17.87. The company has a debt-to-equity ratio of 0.11, a current ratio of 6.24 and a quick ratio of 5.13.
Institutional Trading of Outset Medical
A number of institutional investors and hedge funds have recently made changes to their positions in OM. Assetmark Inc. increased its position in shares of Outset Medical by 387.1% in the second quarter. Assetmark Inc. now owns 1,812 shares of the company’s stock valued at $27,000 after buying an additional 1,440 shares in the last quarter. Point72 Hong Kong Ltd purchased a new stake in shares of Outset Medical during the second quarter worth approximately $27,000. Nisa Investment Advisors LLC increased its position in shares of Outset Medical by 139.5% during the second quarter. Nisa Investment Advisors LLC now owns 2,060 shares of the company’s stock worth $31,000 after purchasing an additional 1,200 shares in the last quarter. Tower Research Capital LLC TRC increased its position in shares of Outset Medical by 38.4% during the third quarter. Tower Research Capital LLC TRC now owns 3,016 shares of the company’s stock worth $48,000 after purchasing an additional 837 shares in the last quarter. Finally, US Bancorp DE increased its position in shares of Outset Medical by 56.6% during the third quarter. US Bancorp DE now owns 4,068 shares of the company’s stock worth $65,000 after purchasing an additional 1,471 shares in the last quarter.
Analyst Upgrades and Downgrades
About Outset Medical
Outset Medical, Inc, a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings.
- Get a free copy of the StockNews.com research report on Outset Medical (OM)
- Is the 60/40 Portfolio Mix Still in Vogue?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Three CBD Stocks to Dominate a Budding Industry
- Microsoft Shares: Is it Time to Back Up the Truck?
- Institutional Support for Analog Devices Remains High
Receive News & Ratings for Outset Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outset Medical and related companies with MarketBeat.com's FREE daily email newsletter.